JP2018505223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505223A5 JP2018505223A5 JP2017560891A JP2017560891A JP2018505223A5 JP 2018505223 A5 JP2018505223 A5 JP 2018505223A5 JP 2017560891 A JP2017560891 A JP 2017560891A JP 2017560891 A JP2017560891 A JP 2017560891A JP 2018505223 A5 JP2018505223 A5 JP 2018505223A5
- Authority
- JP
- Japan
- Prior art keywords
- gvax
- inhibitor
- immunotherapeutic agent
- yap
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115414P | 2015-02-12 | 2015-02-12 | |
| US62/115,414 | 2015-02-12 | ||
| PCT/US2016/017697 WO2016130889A1 (en) | 2015-02-12 | 2016-02-12 | Inhibition of yap for breaking tumor immune tolerance |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020107702A Division JP7186196B2 (ja) | 2015-02-12 | 2020-06-23 | 腫瘍免疫寛容を破綻させるためのｙａｐの阻害方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018505223A JP2018505223A (ja) | 2018-02-22 |
| JP2018505223A5 true JP2018505223A5 (enExample) | 2019-03-28 |
Family
ID=56615092
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560891A Pending JP2018505223A (ja) | 2015-02-12 | 2016-02-12 | 腫瘍免疫寛容を破綻させるためのｙａｐの阻害方法 |
| JP2020107702A Active JP7186196B2 (ja) | 2015-02-12 | 2020-06-23 | 腫瘍免疫寛容を破綻させるためのｙａｐの阻害方法 |
| JP2022117957A Active JP7509830B2 (ja) | 2015-02-12 | 2022-07-25 | 腫瘍免疫寛容を破綻させるためのｙａｐの阻害方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020107702A Active JP7186196B2 (ja) | 2015-02-12 | 2020-06-23 | 腫瘍免疫寛容を破綻させるためのｙａｐの阻害方法 |
| JP2022117957A Active JP7509830B2 (ja) | 2015-02-12 | 2022-07-25 | 腫瘍免疫寛容を破綻させるためのｙａｐの阻害方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11491139B2 (enExample) |
| EP (1) | EP3256123B1 (enExample) |
| JP (3) | JP2018505223A (enExample) |
| CN (1) | CN107635582B (enExample) |
| AU (2) | AU2016219161A1 (enExample) |
| CA (1) | CA2976377A1 (enExample) |
| WO (1) | WO2016130889A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170085619A (ko) * | 2016-01-14 | 2017-07-25 | 연세대학교 산학협력단 | Alk 저해제에 대한 내성을 획득한 eml4-alk 양성 비소세포폐암의 치료를 위한 스타틴계 약물의 용도 |
| US10925869B2 (en) | 2016-05-26 | 2021-02-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Compositions and methods for treating pulmonary vascular disease |
| WO2018085275A1 (en) * | 2016-11-02 | 2018-05-11 | The Regents Of The University Of California | Targeting lats1/2 and the hippo intracellular signaling pathway for cancer immunotherapy |
| JP6886278B2 (ja) * | 2016-12-01 | 2021-06-16 | 学校法人慶應義塾 | 抗癌剤 |
| WO2018119418A1 (en) * | 2016-12-24 | 2018-06-28 | Nivien Therapeutics Company | Methods relating to the treatment of chemoresistant and immuno-resistant cancer |
| EP3568150A4 (en) * | 2017-01-10 | 2020-12-02 | Xcella Biosciences, Inc. | POLYTHERAPY FOR TUMOR TREATMENT WITH INTEGRIN-BOUND FC FUSION PROTEIN AND IMMUNE MODULATOR |
| EP3713569B1 (en) * | 2017-11-22 | 2024-03-13 | University of Pittsburgh- Of the Commonwealth System of Higher Education | Therapeutic particle comprising a yap1/wwrt1 inhibiting agent and the glutaminase inhibiting agent 2-cyclopropyl-n-[5-(4-{ [5-(2-phenylacetamido)-1,3,4-thiadiazol-2-yl]amino}piperidin-1-yl)-1,3,4-thiadiazol-2-yl] acetamide and use thereof for treating a pulmonary disease |
| US11360080B2 (en) * | 2018-08-17 | 2022-06-14 | National Health Research Institutes | AhR-ROR-γt complex as a biomarker and therapeutic target for autoimmune disease and IL-17A-associated disease |
| TW202214854A (zh) * | 2019-01-31 | 2022-04-16 | 美商Ionis製藥公司 | Yap1表現之調節劑 |
| WO2020214650A1 (en) * | 2019-04-15 | 2020-10-22 | Trustees Of Boston University | Methods and compositions for modulating the immune system |
| US20210338265A1 (en) * | 2020-04-30 | 2021-11-04 | Ethicon, Inc. | Methods and devices for delivering cancer therapy to a target tissue site via a cored tissue cavity |
| JP7514508B2 (ja) * | 2020-05-19 | 2024-07-11 | 国立大学法人鳥取大学 | 胆道がん治療薬 |
| US12653785B2 (en) | 2020-05-21 | 2026-06-16 | University of Pittsburgh—of the Commonwealth System of Higher Education | Compositions and methods for administering a YAP1/WWRT1 inhibiting composition and a GLS1 inhibiting composition |
| AU2021372270A1 (en) * | 2020-10-28 | 2023-06-22 | Baylor College Of Medicine | Targeting of src-3 in immune cells as an immunomodulatory therapeutic for the treatment of cancer |
| CN113456633A (zh) * | 2021-06-11 | 2021-10-01 | 广西医科大学 | 红海海绵素a在制备抗肺癌侵袭转移药物中的应用 |
| CN118105483B (zh) * | 2024-02-02 | 2025-03-11 | 济宁医学院附属医院 | Ox40激活抗体和抗血管生成剂在制备抗肿瘤药物中的应用 |
| WO2026071140A1 (ja) * | 2024-09-30 | 2026-04-02 | 日東電工株式会社 | Ｙａｐ１阻害剤およびｗｗｔｒ１阻害剤の両方に対する対象の応答のモニタリング方法、層別化方法およびそれらの補助方法、ならびにｐｃｓｋ９発現阻害剤およびｐｃｓｋ９関連疾患の治療または予防用組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0605685D0 (en) * | 2006-03-21 | 2006-05-03 | Lytix Biopharma As | Inhibition of tumour growth |
| DE60334303D1 (de) * | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| US20040110731A1 (en) * | 2002-12-04 | 2004-06-10 | Chan Agnes H. | Photodynamic therapy for the treatment of non-melanoma skin cancer |
| JP2010504356A (ja) * | 2006-09-20 | 2010-02-12 | ザ ジョンズ ホプキンス ユニバーシティー | 抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法 |
| KR101050829B1 (ko) * | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| WO2011017809A1 (en) * | 2009-08-11 | 2011-02-17 | The University Of British Columbia | Autophagy inhibitor compounds, compositions and methods for the use thereof in the treatment of cancer |
| US20150157584A1 (en) * | 2012-06-11 | 2015-06-11 | The J. David Gladstone Institutes | Inhibitors of hippo-yap signaling pathway |
-
2016
- 2016-02-12 WO PCT/US2016/017697 patent/WO2016130889A1/en not_active Ceased
- 2016-02-12 US US15/549,943 patent/US11491139B2/en active Active
- 2016-02-12 AU AU2016219161A patent/AU2016219161A1/en not_active Abandoned
- 2016-02-12 CA CA2976377A patent/CA2976377A1/en active Pending
- 2016-02-12 CN CN201680021504.9A patent/CN107635582B/zh active Active
- 2016-02-12 JP JP2017560891A patent/JP2018505223A/ja active Pending
- 2016-02-12 EP EP16749939.1A patent/EP3256123B1/en active Active
-
2020
- 2020-06-23 JP JP2020107702A patent/JP7186196B2/ja active Active
-
2021
- 2021-06-10 AU AU2021203851A patent/AU2021203851B2/en active Active
-
2022
- 2022-07-25 JP JP2022117957A patent/JP7509830B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
| WO2021097365A3 (en) | Antigen-binding proteins targeting shared neoantigens | |
| JOP20200312A1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| NO20055347L (no) | Blandinger og framgangsmate for WT1-spesifikk immunterapi | |
| MX2022003005A (es) | Composiciones y metodos de anticuerpos anti-cd39. | |
| RU2017117664A (ru) | Комбинация | |
| EA201791675A1 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
| BR112012023010A8 (pt) | Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37 | |
| CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| EP4623992A3 (en) | Antibodies specifically binding to human il-1r7 | |
| TR201819812T4 (tr) | Kanserin Tedavisi Ve/Veya Önlenmesi Amacına Yönelik Farmasötik Bileşim | |
| MA41038B1 (fr) | Composés d'aminopyridyloxypyrazole | |
| Hazama et al. | Current status of immunotherapy against gastrointestinal cancers and its biomarkers: perspective for precision immunotherapy | |
| MX2014001370A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| EA202091514A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR | |
| JP2013166763A5 (enExample) | ||
| BR112016020009A2 (pt) | anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma | |
| MX2019014316A (es) | Un nuevo anticuerpo anti-c-met y uso del mismo. | |
| UA99602C2 (ru) | Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток | |
| EP4599893A3 (en) | Cg0070 for treating bcg resistant bladder carcinoma in situ | |
| EP4678660A3 (en) | Antibody against activin receptor type ii receptor for use in treating heart failure | |
| BR112019024719A2 (pt) | Composições e métodos para resposta imunológica antitumor aprimorada | |
| JP2015512412A5 (enExample) | ||
| WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use |